Insmed Incorporated (INSM)

$73.81

+1.14

(+1.57%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $71.12
    $74.02
    $73.81
    downward going graph

    3.64%

    Downside

    Day's Volatility :3.92%

    Upside

    0.28%

    downward going graph
  • $21.92
    $80.53
    $73.81
    downward going graph

    70.3%

    Downside

    52 Weeks Volatility :72.78%

    Upside

    8.34%

    downward going graph

Returns

PeriodInsmed IncorporatedSector (Health Care)Index (Russel 2000)
3 Months
-6.58%
-6.9%
0.0%
6 Months
205.5%
-1.7%
0.0%
1 Year
211.04%
10.4%
0.0%
3 Years
151.91%
8.8%
-24.1%

Highlights

Market Capitalization
13.2B
Book Value
$2.70
Earnings Per Share (EPS)
-5.55
PEG Ratio
0.0
Wall Street Target Price
88.869
Profit Margin
-252.01%
Operating Margin TTM
-212.73%
Return On Assets TTM
-26.05%
Return On Equity TTM
-890.75%
Revenue TTM
343.0M
Revenue Per Share TTM
2.21
Quarterly Revenue Growth YOY
18.2%
Gross Profit TTM
190.2M
EBITDA
-695.1M
Diluted Eps TTM
-5.55
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.34
EPS Estimate Next Year
-4.17
EPS Estimate Current Quarter
-1.22
EPS Estimate Next Quarter
-1.16

Analyst Recommendation

Buy
    95%Buy
    4%Hold
    0
    0%Sell
Based on 23 Wall street analysts offering stock ratings for Insmed Incorporated(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
22
21
19
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 20.4%

Current $73.81
Target $88.87

Company Financials

FY18Y/Y Change
Revenue
9.8M
-
Net Income
-324.3M
↑ 68.33%
Net Profit Margin
-3.3K%
-
FY19Y/Y Change
Revenue
136.5M
↑ 1287.56%
Net Income
-254.3M
↓ 21.57%
Net Profit Margin
-186.37%
↑ 3110.8%
FY20Y/Y Change
Revenue
164.4M
↑ 20.48%
Net Income
-294.1M
↑ 15.63%
Net Profit Margin
-178.87%
↑ 7.5%
FY21Y/Y Change
Revenue
188.5M
↑ 14.63%
Net Income
-434.7M
↑ 47.8%
Net Profit Margin
-230.63%
↓ 51.76%
FY22Y/Y Change
Revenue
245.4M
↑ 30.19%
Net Income
-481.5M
↑ 10.79%
Net Profit Margin
-196.26%
↑ 34.37%
FY23Y/Y Change
Revenue
305.2M
↑ 24.39%
Net Income
-749.6M
↑ 55.66%
Net Profit Margin
-245.59%
↓ 49.33%
Q2 FY23Q/Q Change
Revenue
77.2M
↑ 18.42%
Net Income
-244.8M
↑ 53.23%
Net Profit Margin
-316.99%
↓ 72.01%
Q3 FY23Q/Q Change
Revenue
79.1M
↑ 2.39%
Net Income
-158.9M
↓ 35.08%
Net Profit Margin
-201.0%
↑ 115.99%
Q4 FY23Q/Q Change
Revenue
83.7M
↑ 5.84%
Net Income
-186.1M
↑ 17.07%
Net Profit Margin
-222.31%
↓ 21.31%
Q1 FY24Q/Q Change
Revenue
75.5M
↓ 9.79%
Net Income
-157.1M
↓ 15.57%
Net Profit Margin
-208.07%
↑ 14.24%
Q2 FY24Q/Q Change
Revenue
90.3M
↑ 19.66%
Net Income
-300.6M
↑ 91.36%
Net Profit Margin
-332.75%
↓ 124.68%
Q3 FY24Q/Q Change
Revenue
93.4M
↑ 3.41%
Net Income
-220.5M
↓ 26.64%
Net Profit Margin
-236.04%
↑ 96.71%
FY18Y/Y Change
Total Assets
604.6M
↑ 30.84%
Total Liabilities
396.3M
↑ 292.41%
FY19Y/Y Change
Total Assets
742.3M
↑ 22.78%
Total Liabilities
480.6M
↑ 21.28%
FY20Y/Y Change
Total Assets
796.2M
↑ 7.26%
Total Liabilities
520.3M
↑ 8.25%
FY21Y/Y Change
Total Assets
1.2B
↑ 56.19%
Total Liabilities
833.0M
↑ 60.12%
FY22Y/Y Change
Total Assets
1.7B
↑ 33.21%
Total Liabilities
1.6B
↑ 88.28%
FY23Y/Y Change
Total Assets
1.3B
↓ 19.72%
Total Liabilities
1.7B
↑ 5.95%
Q2 FY23Q/Q Change
Total Assets
1.4B
↓ 5.18%
Total Liabilities
1.6B
↑ 2.08%
Q3 FY23Q/Q Change
Total Assets
1.3B
↓ 7.94%
Total Liabilities
1.6B
↑ 1.21%
Q4 FY23Q/Q Change
Total Assets
1.3B
↑ 0.37%
Total Liabilities
1.7B
↑ 2.94%
Q1 FY24Q/Q Change
Total Assets
1.2B
↓ 12.84%
Total Liabilities
1.6B
↓ 2.28%
Q2 FY24Q/Q Change
Total Assets
1.8B
↑ 56.17%
Total Liabilities
1.8B
↑ 9.08%
Q3 FY24Q/Q Change
Total Assets
2.1B
↑ 13.42%
Total Liabilities
1.6B
↓ 11.39%
FY18Y/Y Change
Operating Cash Flow
-258.0M
↑ 61.62%
Investing Cash Flow
-14.8M
↑ 393.64%
Financing Cash Flow
386.7M
↑ 1.48%
FY19Y/Y Change
Operating Cash Flow
-250.6M
↓ 2.84%
Investing Cash Flow
-42.3M
↑ 185.32%
Financing Cash Flow
285.3M
↓ 26.24%
FY20Y/Y Change
Operating Cash Flow
-219.3M
↓ 12.49%
Investing Cash Flow
-6.8M
↓ 83.86%
Financing Cash Flow
271.0M
↓ 5.0%
FY21Y/Y Change
Operating Cash Flow
-363.3M
↑ 65.63%
Investing Cash Flow
-64.3M
↑ 842.32%
Financing Cash Flow
612.5M
↑ 126.03%
FY22Y/Y Change
Operating Cash Flow
-400.4M
↑ 10.22%
Investing Cash Flow
-34.6M
↓ 46.2%
Financing Cash Flow
793.3M
↑ 29.5%
Q2 FY23Q/Q Change
Operating Cash Flow
-122.8M
↓ 16.07%
Investing Cash Flow
-274.2M
↓ 759.0%
Financing Cash Flow
44.3M
↓ 11209.27%

Technicals Summary

Sell

Neutral

Buy

Insmed Incorporated is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Insmed Incorporated
Insmed Incorporated
0.18%
205.5%
211.04%
151.91%
247.34%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-22.64%
-24.32%
-6.91%
15.67%
106.43%
Biontech Se
Biontech Se
-2.39%
5.8%
10.48%
-66.36%
407.41%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-16.76%
63.55%
51.52%
31.97%
130.85%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.17%
0.63%
27.5%
148.14%
106.59%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Insmed Incorporated
Insmed Incorporated
NA
NA
0.0
-5.34
-8.91
-0.26
NA
2.7
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.38
18.38
1.11
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.18
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Insmed Incorporated
Insmed Incorporated
Buy
$13.2B
247.34%
NA
-252.01%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.7B
106.43%
18.38
33.61%
Biontech Se
Biontech Se
Buy
$24.5B
407.41%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.1B
130.85%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.2B
106.59%
32.84
-4.51%

Insights on Insmed Incorporated

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 75.5M → 93.42M (in $), with an average increase of 9.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -300.60M → -220.52M (in $), with an average increase of 36.3% per quarter

Institutional Holdings

  • Vanguard Group Inc

    9.58%

  • BlackRock Inc

    7.97%

  • T. Rowe Price Associates, Inc.

    6.80%

  • FMR Inc

    4.02%

  • Capital Research & Mgmt Co - Division 3

    3.65%

  • State Street Corp

    2.61%

Corporate Announcements

  • Insmed Incorporated Earnings

    Insmed Incorporated’s price-to-earnings ratio stands at None

    Read More

Company Information

insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.

Organization
Insmed Incorporated
Employees
912
CEO
Mr. William H. Lewis J.D., M.B.A.
Industry
Health Technology

FAQs